Current Sleep Medicine Reports

, Volume 5, Issue 1, pp 23–32 | Cite as

A Case-Based Approach to the Identification and Treatment of Sleep Disorders in Neurology Practice

  • José Rafael P. ZuzuárreguiEmail author
  • Emmanuel H. During
Sleep and Neurological Conditions (A Avidan, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Sleep and Neurological Conditions


Purpose of Review

We present a case-based approach to common sleep disorders encountered in the clinic.

Recent Findings

Sleep disorders are common in neurologic disease and may result from the disease itself or serve as a marker for potential neurologic disease. These include, but are not limited to, rapid eye movement sleep behavior disorder, restless legs syndrome, obstructive sleep apnea, and insomnia. A review of these disorders and their clinical presentation is presented. Treatment options and ethical considerations based on current research and clinical guidelines are reviewed and discussed.


Understanding of the pathophysiology and treatment of sleep disorders in neurologic disease continues to remain somewhat poorly understood. Though recent breakthroughs have helped to guide therapy for these disorders, research in these areas is needed. Consensus guidelines have been developed to help guide the physician and their management of common sleep disorders encountered in the clinic.


Rapid eye movement sleep behavior disorder (RBD) Restless legs syndrome (RLS) Obstructive sleep apnea (OSA) Insomnia Circadian rhythm disorder 


Author Contributions

Drs. Zuzuárregui and During were responsible for the study concept, analysis, and interpretation of the data and contributed to drafting and revising of the manuscript.

Compliance with Ethical Standards

Conflict of Interest

José Rafael P. Zuzuárregui and Emmanuel H. During each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9(2):293–308.Google Scholar
  2. 2.
    Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54.Google Scholar
  3. 3.
    •• Fernández-Arcos A, Iranzo A, Serradell M, Gaig C, Santamaria J. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. Sleep. 2016;39(1):121–32 This is the largest study to evaluate patients with idiopathic rapid eye movement sleep behavior disorder and the subsequent development of neurodegenerative disease. Google Scholar
  4. 4.
    Saper CB. The neurobiology of sleep. Continuum (Minneap Minn). 2013;19(1 Sleep Disorders):19–31.Google Scholar
  5. 5.
    Iranzo A. The REM sleep circuit and how its impairment leads to REM sleep behavior disorder. Cell Tissue Res. 2018;373(1):245–66.Google Scholar
  6. 6.
    Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol. 2018;14(1):40–55. Review.Google Scholar
  7. 7.
    Arnaldi D, Antelmi E, St Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: to tell or not to tell to the patient? How to minimize the risk? Sleep Med Rev. 2017;36:82–95.Google Scholar
  8. 8.
    Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.Google Scholar
  9. 9.
    McCarter SJ, St Louis EK, Sandness DJ, Arndt K, Erickson M, Tabatabai G, et al. Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behavior disorder. Sleep. 2015;38(6):907–17.Google Scholar
  10. 10.
    Teman PT, Tippmann-Peikert M, Silber MH, Slocumb NL, Auger RR. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med. 2009;10(1):60–5.Google Scholar
  11. 11.
    Bugalho P, Mendonça M, Barbosa R, Salavisa M. The influence of sleep disordered breathing in REM sleep behavior disorder. Sleep Med. 2017;37:210–5.Google Scholar
  12. 12.
    Jung Y, St Louis EK. Treatment of REM sleep behavior disorder. Curr Treat Options Neurol. 2016;18(11):50.Google Scholar
  13. 13.
    Ferri R, Marelli S, Ferini-Strambi L, Oldani A, Colli F, Schenck CH, et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med. 2013;14(1):24–9.Google Scholar
  14. 14.
    Standards of Practice Committee, Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.Google Scholar
  15. 15.
    McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19–26.Google Scholar
  16. 16.
    Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–6.Google Scholar
  17. 17.
    Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–81.Google Scholar
  18. 18.
    Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord. 2012;27(4):559–61.Google Scholar
  19. 19.
    Brunetti V, Losurdo A, Testani E, Lapenta L, Mariotti P, Marra C, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res. 2014;11(3):267–73.Google Scholar
  20. 20.
    St Louis EK, Boeve BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc. 2017;92(11):1723–36.Google Scholar
  21. 21.
    Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson’s disease dementia. Int J Geriatr Psychiatry. 2010;25(10):1030–8.Google Scholar
  22. 22.
    Abenza Abildúa MJ, Miralles Martinez A, Arpa Gutiérrez FJ, Lores Gutiérrez V, Algarra Lucas C, Jimeno Montero C, Sánchez García B, Mata Álvarez-Santullano M, Borrue Fernández C, Cordero Martín G, Gutiérrez Cueto G, Torrecillas Narváez MD, Thuissard Vasallo I, Gómez Aceña A. Conditions associated with REM sleep behaviour disorder: description of a hospital series. Neurologia 2017.Google Scholar
  23. 23.
    Gabryelska A, Roguski A, Simpson G, Maschauer EL, Morrison I, Riha RL. Prevalence of obstructive sleep apnoea in REM behaviour disorder: response to continuous positive airway pressure therapy. Sleep Breath. 2018;22(3):825–30.Google Scholar
  24. 24.
    Vertrees S, Greenough GP. Ethical considerations in REM sleep behavior disorder. Continuum (Minneap Minn). 2013;19(1 Sleep Disorders):199–203.Google Scholar
  25. 25.
    Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front Neurol. 2018;9:156.Google Scholar
  26. 26.
    Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. International restless legs syndrome study group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated international restless legs syndrome study group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–73.Google Scholar
  27. 27.
    Innes KE, Selfe TK, Agarwal P. Prevalence of restless legs syndrome in north American and Western European populations: a systematic review. Sleep Med. 2011;12(7):623–34.Google Scholar
  28. 28.
    Koo BB. Restless leg syndrome across the globe: epidemiology of the restless legs syndrome/Willis-Ekbom disease. Sleep Med Clin. 2015;10(3):189–205 xi.Google Scholar
  29. 29.
    Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698–700.Google Scholar
  30. 30.
    Daubian-Nose P, Frank MK, Esteves AM. Sleep disorders: a review of the interface between restless legs syndrome and iron metabolism. Sleep Sci. 2014;7:234–7.Google Scholar
  31. 31.
    • Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016;86(14):1336–43 This review evaluates a large number of studies that have evaluated the association of restless legs syndrome with other disorders and highlights the associations that appear to be strong. Google Scholar
  32. 32.
    Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry. 2014;75:e06.Google Scholar
  33. 33.
    Ferini-Strambi L. RLS-like symptoms: differential diagnosis by history and clinical assessment. Sleep Med. 2007;8(Suppl 2):S3–6.Google Scholar
  34. 34.
    Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–5.Google Scholar
  35. 35.
    Silva C, Peralta AR, Bentes C. The urge to move and breathe - the impact of obstructive sleep apnea syndrome treatment in patients with previously diagnosed, clinically significant restless legs syndrome. Sleep Med. 2017;38:17–20.Google Scholar
  36. 36.
    Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG, Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977–86.Google Scholar
  37. 37.
    Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27–44.Google Scholar
  38. 38.
    Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–84.Google Scholar
  39. 39.
    Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord. 2007;22:590–1.Google Scholar
  40. 40.
    Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016;87(24):2585–93.Google Scholar
  41. 41.
    D’Cruz RF, Murphy PB, Kaltsakas G. Sleep disordered breathing in motor neurone disease. J Thorac Dis. 2018;10(Suppl 1):S86–93.Google Scholar
  42. 42.
    Ferguson KA, Strong MJ, Ahmad D, George CF. Sleep-disordered breathing in amyotrophic lateral sclerosis. Chest. 1996;110(3):664–9.Google Scholar
  43. 43.
    • Quaranta VN, Carratù P, Damiani MF, Dragonieri S, Capozzolo A, Cassano A, et al. The prognostic role of obstructive sleep apnea at the onset of amyotrophic lateral sclerosis. Neurodegener Dis. 2017;17(1):14–21 This study highlights the significantly negative impact of the presence of obstructive sleep apnea on survival rates in patients with amyotrophic lateral sclerosis. Google Scholar
  44. 44.
    Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. Neurology. 2001;57(11):2040–4.Google Scholar
  45. 45.
    Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep. 2006;29(3):375–80.Google Scholar
  46. 46.
    Perrin C, D’Ambrosio C, White A, Hill NS. Sleep in restrictive and neuromuscular respiratory disorders. Semin Respir Crit Care Med. 2005;26(1):117–30.Google Scholar
  47. 47.
    Boentert M, Brenscheidt I, Glatz C, Young P. Effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis. J Neurol. 2015;262(9):2073–82.Google Scholar
  48. 48.
    Katzberg HD, Selegiman A, Guion L, Yuan N, Cho SC, Katz JS, et al. Effects of noninvasive ventilation on sleep outcomes in amyotrophic lateral sclerosis. J Clin Sleep Med. 2013;9(4):345–51.Google Scholar
  49. 49.
    Vrijsen B, Buyse B, Belge C, Robberecht W, Van Damme P, Decramer M, et al. Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study. J Clin Sleep Med. 2015;11(5):559–66.Google Scholar
  50. 50.
    Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140–7.Google Scholar
  51. 51.
    Di PWC, Di PSGC. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14(9):883–92.Google Scholar
  52. 52.
    Crespy L, Zaaraoui W, Lemaire M. Prevalence of grey matter pathology in early multiple sclerosis assessed by magnetization transfer ratio imaging. PLoS One. 2011;6(9):e24969. Google Scholar
  53. 53.
    Rocca M, Preziosa P, Copetti M. Gray matter damage predicts the accumulation of disability and cognitive impairment 13 years later in MS. Neurology. 2013;81:1759–67. Google Scholar
  54. 54.
    Krupp LB, Serain DJ. Multiple sclerosis-associated fatigue. W: Multiple Sclerosis Therapeutics, Fourth Edition. T 9780521766272. ; 2011:654–665. doi:
  55. 55.
    Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004;10(2):165–9.Google Scholar
  56. 56.
    Tellez N, Alonso J, Rio J. The basal ganglia: a substrate for fatigue in multiple sclerosis. Neuroradiology. 2008;50(1):17–23. Google Scholar
  57. 57.
    Li Y, Munger KL, Batool-Anwar S, De Vito K, Ascherio A, Gao X. Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women. Neurology. 2012;78(19):1500–6. Scholar
  58. 58.
    Frauscher B, Löscher WN, Högl B, Poewe W, Kofler M. Auditory startle reaction is disinhibited in idiopathic restless legs syndrome. Sleep. 2007;30(4):489–93. Scholar
  59. 59.
    Manconi M, Rocca MA, Ferini-Strambi L. Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler. 2008;14(1):86–93. Google Scholar
  60. 60.
    Qaseem A, Kansagara D, Forciea MA. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2016;165(2):125–33. Scholar
  61. 61.
    Manber R, Carney C, Edinger J. Dissemination of CBTI to the non-sleep specialist: protocol development and training issues. J Clin Sleep Med. 2012;8(2):209–18. Scholar
  62. 62.
    Billioti de Gage S, Moride Y, Ducruet T, in. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 2014;349(sep09 2):g5205–g5205. doi:
  63. 63.
    Braley TJ, Segal BM, Chervin RD. Obstructive sleep apnea and fatigue in patients with multiple sclerosis. J Clin Sleep Med. 2014;10(2):155–62. Google Scholar
  64. 64.
    Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9(4):269–310. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • José Rafael P. Zuzuárregui
    • 1
    Email author
  • Emmanuel H. During
    • 2
  1. 1.Division of Neurology, Fresno Center for Medical Education and ResearchUniversity of CaliforniaFresnoUSA
  2. 2.Stanford Center for Sleep Sciences and Medicine, Department of Psychiatry and Behavioral SciencesStanford University Medical CenterPalo AltoUSA

Personalised recommendations